View on Pubmed.gov 31372089 | View on doi.org 10.2147/DNND.S2...
Effect of the micro-immunotherapy medicine 2LPARK on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson's disease.
- Clinical Affairs, Labo'Life France, Moutiers-Sous-Chantemerle, F-79320, France.
- Syncrosome, Campus Luminy - Luminy Entreprises, Marseille 13288, France.
- Labo'Life Belgium, Parc Scientifique CREALYS, Gembloux 5032, Belgium.
Abstract
BACKGROUND
Parkinson's disease (PD) is a neurodegenerative disease characterized by motor impairments and resulting from progressive degenerative loss of midbrain dopaminergic (DAergic) neurons in the substantia nigra. Although the main cause of the loss of DAergic neurons is still unknown, various etiopathogenic mechanisms are distinguished, including release and accumulation of endogenous excitotoxic mediators along with the production of oxidative free radicals. Several neurotrophic and growth factors are known to increase DAergic neuronal survival and enhance antioxidant mechanisms. In this context, the micro-immunotherapy (MI) approach consists to regulate the immune system in order to protect DAergic neurons and control oxidative stress.
PURPOSE
The aim of the present study was to investigate the effect of the MI medicine (MIM), 2LPARK (Labo'Life), on oxidative stress and on the number of neurons positive for tyrosine hydroxylase (TH), in an in vitro model of PD.
METHODS
Rat primary mesencephalic DAergic neurons cultures were pre-treated for 1 hr with the MIM (10 μM and 10 mM), placebo (10 μM and 10 mM) or brain-derived neurotrophic factor (BDNF; 3.3 μM) and then intoxicated with 6-hydroxydopamine (6-OHDA; 20 μM) for 48 hrs. After incubation, cells were incubated 30 mins at 37°C with CellROX green reagent and number of labeled cells were quantified. Then, cells were fixed and incubated with anti-TH antibody and the number of TH neurons was evaluated.
RESULTS
We showed that, contrary to placebo, MIM was able to reduce oxidative stress and protect DAergic neurons from 6-OHDA-induced cell death.
CONCLUSION
Our results demonstrate the in vitro efficacy of MIM on two essential mechanisms of PD and propose the MI approach as a new ally in the regulation of neuroinflammation and in the treatment of this degenerative disease.
References
Neuroreport. 1999 Feb 25;10(3):557-61
J Biol Chem. 2000 Dec 8;275(49):38581-8
Nature. 2001 May 3;411(6833):86-9
Neurosci Lett. 2001 Dec 28;316(3):129-32
Cited by 10 citations (total)
Journal Article
Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation.
Electronic publication date April 10, 2020
Ilaria Floris [...] Beatrice Lejeune et al.
In this study, we evaluated the efficacy of a micro-immunotherapy medicine (MIM), 2LALERG, in a preclinical model of allergic respiratory...
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Elevated Cellular Oxidative Stress in Circulating Immune Cells in Otherwise Healthy Young People Who Use Electronic Cigarettes in a Cross-Sectional Single-Center Study: Implications for Future Cardiovascular Risk.
Electronic publication date March 11, 2021
Theodoros Kelesidis [...] Holly R Middlekauff et al.
Background Tobacco cigarettes (TCs) increase oxidative stress and inflammation, both instigators of atherosclerotic cardiac disease. It is unknown if electronic...
Conflict of interest statement
NLL works for Labo’Life France, the company service provider for Labo’Life, specializing in preclinical, clinical, and regulatory affairs. NLL reports personal fees during the conduct of the study and outside the submitted work from Labo'Life France. BL is employed by Labo’Life Belgium, the pharmaceutical company that commercializes the micro-immunotherapy medicine tested in the study. BL reports personal fees during the conduct of the study and outside the submitted work from Labo'Life Belgium. NLL and BL declare that their professional relationships with Labo’Life France and Labo’Life Belgium do not imply any misconduct in this study. DR and SR work for Syncrosome, a contract research organization that specializes in preclinical research. The authors report no other conflicts of interest in this work.
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •